A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma.
about
Hsp90: A New Player in DNA Repair?Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancersMolecular mechanisms of action and therapeutic uses of pharmacological inhibitors of HIF-prolyl 4-hydroxylases for treatment of ischemic diseasesHsp90 blockers inhibit adipocyte differentiation and fat mass accumulationThe HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damageHeat shock protein 90 inhibition abrogates hepatocellular cancer growth through cdc2-mediated G2/M cell cycle arrest and apoptosis.Expression-based Pathway Signature Analysis (EPSA): mining publicly available microarray data for insight into human disease.Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumorsDevelopment and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasmaA 20-year-old female with hemoptysis and high blood pressure: An unusual case of papillary renal cell carcinoma.Biodistribution of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer drug delivery.Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycinComparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluationHeat shock protein 90 inhibitors in the treatment of cancer: current status and future directionsThe heat shock protein 90 inhibitor 17-AAG suppresses growth and induces apoptosis in human cholangiocarcinoma cells.In Vitro Activity of Geldanamycin Derivatives against Schistosoma japonicum and Brugia malayiMTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors.The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies.Heat shock transcription factor 1-activating compounds suppress polyglutamine-induced neurodegeneration through induction of multiple molecular chaperones.Autophagy is involved in endogenous and NVP-AUY922-induced KIT degradation in gastrointestinal stromal tumors.Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64)Cu-DOTA-trastuzumab.Arsenite-induced mitotic death involves stress response and is independent of tubulin polymerization.Heat shock proteins in the retina: Focus on HSP70 and alpha crystallins in ganglion cell survival.Enzymatic reduction and glutathione conjugation of benzoquinone ansamycin heat shock protein 90 inhibitors: relevance for toxicity and mechanism of action.Stability of the Hsp90 inhibitor 17AAG hydroquinone and prevention of metal-catalyzed oxidation.Selective Raf inhibition in cancer therapy.Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer.Synergism of heat shock protein 90 and histone deacetylase inhibitors in synovial sarcoma.Effects of treatment with an Hsp90 inhibitor in tumors based on 15 phase II clinical trials.New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response.The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumorsThe role of molecular chaperones in human misfolding diseases.Characterization of celastrol to inhibit hsp90 and cdc37 interaction.Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies.Targetable HPMA copolymer-aminohexylgeldanamycin conjugates for prostate cancer therapy.Hsp90 as a therapeutic target in patients with oesophageal carcinoma.Chronic treatment with 17-DMAG improves balance and coordination in a new mouse model of Machado-Joseph disease.
P2860
Q26778944-05DC42CF-F584-4BB3-8A83-2DB847CAE975Q27022514-84653511-8079-466C-804D-DC29B8742DC8Q28297656-33DBA6EB-421D-46C5-B096-428D47AFD357Q28542000-3D7ADDF6-5624-4596-BD47-6C979D0B49B5Q28730558-1C518181-54D4-47AE-B88E-0E7A3CB41731Q30585904-CD00F525-5049-420F-A3C0-6D21DBFF02FEQ33378247-811687A0-9938-4B26-8E48-D1368081B12CQ33387877-DF25C8B1-5ED8-48CB-B4D1-43F730D30DE3Q33440318-EDA87D51-2A7D-4149-9024-493E643D2F4DQ33773403-A93127A1-57B7-4ACF-B86E-8737F28FC977Q33836864-6778335A-1C95-4C44-B0BA-8B6D6F61FA20Q34018372-B5B26D68-2B6F-46E9-A724-7F39F15B0CBAQ34102029-A8763C2F-F4C2-413E-B542-C160C2663A42Q34164027-C03A5F90-7ACB-4C18-8216-0CDD94452E2EQ34407501-AE42E5E4-C9E9-40EC-B15D-755A5DBC223CQ34495415-F85A9998-4A40-4BC6-969E-EE30E8419009Q34957090-9FA41703-3C06-4EAB-9639-B6EB42A568B4Q35444159-9FD2A32B-A8E2-4F40-A9C0-510C2627A71FQ35674426-C8E2CE2D-0156-4F83-8CB3-2FFCCEA678F0Q36556257-A87C17A0-1D3C-4187-8D5E-7F41266CBB8DQ36680209-88ECEB8F-1F09-44DB-A45D-149C19744AD0Q36824250-E6C9C416-4696-4DB1-B8A8-56321274290CQ36829093-0871CF69-3779-400F-9361-29091404C8D9Q36953062-B4B85869-1BE3-47A2-BD14-2DBBDF181F47Q36967257-8CAF0D4F-9B18-4E58-BB13-E9EF245D0042Q37004743-BD06C214-2443-4DD8-8FEA-77BC34B712F9Q37068863-4B5D6741-1C08-4E15-AED4-DB8A65C1991FQ37092020-36DFFD7F-0ED7-413B-9ABC-0EE3FA4040E9Q37138320-BB42784E-A262-4D9B-ACA8-3C6705E1D697Q37204596-651D36AC-A109-451D-949B-E8DF64ED34F2Q37215989-03B83D0F-AFE1-471C-8561-610E9CC13E45Q37226339-CE5AA3E8-71D2-486D-9D2F-576E20C57EB4Q37333665-EB825A37-4994-41AA-8F42-7C8CD85D0DF5Q37459598-BAFB73BC-637E-4CAB-A7BF-BBC33460FCBEQ37467557-7B8BF504-C440-45CE-A11A-55A132E45009Q37494634-5289AA5C-C91A-42E1-BC94-353FBC3DD2F0Q37594553-9CA89B91-16B0-4605-8BB8-A63753F63714Q37635384-481867C5-F517-4CFF-8CA9-BD2FB94B6468Q37690758-9364A1DD-BD3E-47D8-9D98-96FB4226B618Q37717405-CB5E0287-E8C7-4B24-AF13-65A9B06492F3
P2860
A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
A phase II trial of 17-
@nl
A phase II trial of 17-(Allyla ...... ear cell renal cell carcinoma.
@en
type
label
A phase II trial of 17-
@nl
A phase II trial of 17-(Allyla ...... ear cell renal cell carcinoma.
@en
prefLabel
A phase II trial of 17-
@nl
A phase II trial of 17-(Allyla ...... ear cell renal cell carcinoma.
@en
P2093
P1476
A phase II trial of 17-(Allyla ...... ear cell renal cell carcinoma.
@en
P2093
Ellen A Ronnen
G Varuni Kondagunta
Jennifer Bacik
John K Deluca
Lawrence Schwartz
Nicole Ishill
Suzanne M Sweeney
P2888
P304
P356
10.1007/S10637-006-9208-Z
P577
2006-11-01T00:00:00Z